Thursday, November 14, 2024 at 2-3pm ET                             Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Major Depressive Disorder (MDD) is a disabling mental health condition with an annual prevalence of 10.4% and a lifetime prevalence of 20.6% in the US. This is associated with a high economic burden, which has increased significantly over the last decade, comprising direct and indirect costs, due to lost productivity. MDD also results in considerable burden to patients, with social, emotional, and physical problems; cognitive difficulties; changes in sleep and eating patterns; and can impact patients' quality of life. Many MDD patients require augmentation of their antidepressant with an additional therapy, and augmentation with an atypical antipsychotic is a guideline-recommended option for appropriate MDD patients. This session will focus on the burden of MDD, as well as the pharmacology, efficacy, and safety of an adjunctive treatment for MDD.

Learning Objectives

• Recognize the humanistic and economic burden of major depressive disorder (MDD).
• Describe where atypical antipsychotics fit within the treatment paradigm.
• Review the pharmacology and efficacy/safety of an adjunctive treatment for MDD in adults.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.